trending Market Intelligence /marketintelligence/en/news-insights/trending/7SQmencI_BGVDqMiLtJ6Vw2 content esgSubNav
In This List

Qiagen sticking to stand-alone business plan after completing strategic review

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Qiagen sticking to stand-alone business plan after completing strategic review

Qiagen NV's board has determined, after completing a strategic review, that the company's current stand-alone business plan "represents the best opportunity to drive future value creation."

The supervisory and management board of Netherlands-based Qiagen, which provides solutions for molecular testing for the diagnosis of diseases and the development of treatments, started discussions with interested parties to explore strategic alternatives to maximize shareholder value.

This process was announced in mid-November after Qiagen received several conditional, non-binding indications of interest for a full acquisition. Bloomberg News had reported earlier that Thermo Fisher Scientific Inc. reached out to Qiagen with a potential deal.

Qiagen's board decided that the alternatives to the stand-alone prospects were not compelling and has terminated all discussions so that the company's management can focus on executing the stand-alone plan.